Hebang Biotech said at the 2026 semi-annual results briefing held on October 12 that since the second half of the year, production and sales of the company's phosphate products have been normal, and there is no risk that sales prices and gross margin expectations will fluctuate greatly. Supply, demand and prices in the glyphosate industry are affected by multiple factors. The company maintains normal production and operation, and the diglyphosate and glyphosate production lines are producing at full capacity. This year, the company focuses on removing inventory and revitalizing cash flow, but the shipment volume will be adjusted in a timely manner according to market forecasts. There is uncertainty about the impact of climate phenomena such as El Niño on global demand for agriculture and herbicides.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.